CDC panel recommends Bavarian Nordic's mpox vaccine for all adults at risk
Reuters
Published Feb 22, 2023 03:23PM ET
Updated Feb 22, 2023 03:40PM ET
(Reuters) - Advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday voted in favor of use of Bavarian Nordic's Jynneos vaccine for all adults at risk of mpox during an outbreak.
The panel of outside experts voted unanimously in favor of use of two doses of the vaccine, and finalizing the interim guidelines provided by CDC during the mpox outbreak in the United States.
The recommendation of the committee is based on studies that showed vaccine effectiveness of 66%-83% for patients with full vaccination and 36%-86% for partial vaccination with no severe adverse affect.
The intradermal injection of Jynneos – that is between the layers of skin – is the preferred form of administration for adults during the outbreak, but is also approved as a subcutaneous injection, or below the skin.
The panel's recommendation will give Bavarian Nordic's vaccine an edge over Emergent BioSolutions' smallpox vaccine, which last year received approval for expanded use during mpox outbreak but its use has been largely limited owing to severe side-effects.
Mpox which spreads via close contact and tends to cause flu-like symptoms and pus-filled skin lesions, remains a public health emergency of international concern as World Health Organization earlier this month retained its highest level of alert for the disease citing continued transmission in some countries.
In the United States, more than 29,000 cases of mpox were reported last year, including two deaths, according to government data.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.